US vaccine candidate Moderna has achieved 100 per cent efficacy against severe COVID-19 disease and has filed an application for “Emergency Use Authorisation” with the US Food and Drug Administration.

It follows Pfizer/BioNTech to become the second vaccine maker to request such an authorisation.